Analysis of EBV specificity within the patient CTL lines
EBV protein . | HLA restriction and epitope sequence . | No. of CTL lines, responders/tested (%) . |
|---|---|---|
| EBNA1 | B35: HPV | 1/3 (33) |
| EBNA2 | A2: DTP | 0/9 (0) |
| EBNA3A | A2: SVR; A3: RLR; B7: RPP, VPA; B8: QAK, FLR; B35: YPL | 4/16 (25) |
| EBNA3B | A11: AVF, IVT, LPG, DEP, NPT; A24: TYS; B35: AVL; B44: VEI | 3/8 (37.5) |
| EBNA3C | A2: LLD; B27: FRK; B44: EEN | 0/13 (0) |
| LMP2 | A2: CLG; A11: SSC; A24: TYG; B27: RRR; B35: MSG | 5/17 (29) |
| BMLF1, BZLF1, BRLF1 | A2: GLC, YVL, TLD; A3: RVR, KHS; A11: ATI; A24: DYC; B8: RAK; B35: EPL | 13/17 (76) |
EBV protein . | HLA restriction and epitope sequence . | No. of CTL lines, responders/tested (%) . |
|---|---|---|
| EBNA1 | B35: HPV | 1/3 (33) |
| EBNA2 | A2: DTP | 0/9 (0) |
| EBNA3A | A2: SVR; A3: RLR; B7: RPP, VPA; B8: QAK, FLR; B35: YPL | 4/16 (25) |
| EBNA3B | A11: AVF, IVT, LPG, DEP, NPT; A24: TYS; B35: AVL; B44: VEI | 3/8 (37.5) |
| EBNA3C | A2: LLD; B27: FRK; B44: EEN | 0/13 (0) |
| LMP2 | A2: CLG; A11: SSC; A24: TYG; B27: RRR; B35: MSG | 5/17 (29) |
| BMLF1, BZLF1, BRLF1 | A2: GLC, YVL, TLD; A3: RVR, KHS; A11: ATI; A24: DYC; B8: RAK; B35: EPL | 13/17 (76) |